Good AI Capital

Aether Bio is a technology company that focuses on re-purposing enzymes to create new compounds using machine learning. By integrating machine learning with high-throughput robotic laboratories, Aether Bio engineers enzymes rapidly and enables massively parallelized experimentation. This innovative approach generates significantly larger datasets compared to competitors, allowing researchers to manufacture complex and novel products more efficiently and at a lower cost. The company's technology aims to provide healthcare institutions with sustainable and affordable chemicals and materials essential for their operations.

Serve Robotics is a company focused on developing self-driving robotic carriers tailored for last-mile delivery services, particularly in the food sector. Its flagship product is a zero-emission robot designed to operate in public spaces, enhancing the delivery experience for customers. The company leverages an advanced AI-robotics mobility platform to facilitate efficient delivery operations in urban environments. Additionally, Serve Robotics collaborates with various platforms and merchants, enabling local businesses to expand their reach and connect with more customers through innovative robotic solutions.

Pragma Bio is a biotechnology company focused on developing microbiome-based therapies for cancer and autoimmune diseases. Founded in 2018 in Millbrae, California, by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti, the company utilizes proprietary genomic sequencing, artificial intelligence, and synthetic biology techniques to identify biomarkers and therapeutics for complex immunologic disorders. Its innovative platform aggregates extensive public and private data to create a microbiome database, enabling the discovery of connections between biologically relevant data. By using this analytical approach, Pragma Bio aims to identify novel biomarkers that can help stratify patient risk and predict clinical outcomes. The company emphasizes the importance of understanding the gut-immune axis and employs machine learning to enhance the drug discovery process, offering a more efficient alternative to traditional methods and aiming to deliver improved medicines to patients more rapidly and cost-effectively.

Stellic Inc. operates an integrated planning and advising platform designed to assist students in navigating their academic journeys effectively. The platform features tools such as a Degree Planner, which includes course search, prerequisite checks, and semester scheduling, along with a Degree Audit that tracks academic progress by calculating completed and remaining requirements. Additionally, the Advisor Tool helps academic advisors identify at-risk students early, while Data Reports provide university administrators with insights into course demand and student performance. Founded by Carnegie Mellon undergraduates frustrated with existing degree planning tools, Stellic aims to enhance the educational experience by offering user-friendly, data-driven solutions tailored for both students and institutions. The company is headquartered in Doha, Qatar, with a presence in Palo Alto, California.

Bit.bio is a synthetic biology company focused on revolutionizing cell therapies by providing consistent and functional human cells for research and medical applications. The company aims to democratize access to these cells through its patented opti-ox™ technology, which safely reprograms human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. By applying computational principles to biology, Bit.bio seeks to develop a scalable platform that produces consistent batches of human cells. This innovation has the potential to enhance drug discovery and research, moving away from traditional models to work directly with the cells impacted by human diseases. With a team of experts in stem cells, cellular reprogramming, and mathematical modeling, Bit.bio is positioned to support a new generation of cell and tissue therapies, ultimately contributing to advancements in health and medicine.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

Playco Global, Inc. is a gaming company that specializes in developing an instant-play gaming platform, enabling multiplayer experiences accessible to billions of users without the need for downloads. Founded in 2010 and based in Mountain View, California, with additional offices in San Francisco, Tokyo, and Seoul, Playco has created a browser-based streaming game engine that allows users to enjoy advanced games across various gaming platforms. The company collaborates with a wide range of partners, from major tech and social media companies to emerging startups, to develop innovative gaming technologies. Playco's focus on seamless multiplayer interactions positions it as a leader in the evolution of social gaming.

Keatext Inc. is a Montreal-based company that offers a cloud-based text analytics platform designed to enhance business performance by analyzing customer feedback from various sources. Established in 2010, Keatext utilizes artificial intelligence and natural language processing to synthesize large volumes of unstructured data, such as open-survey responses, online reviews, chat logs, and social media posts. The platform provides clients with actionable insights through a comprehensive dashboard, enabling them to understand customer sentiments and identify key areas for improvement. By delivering instant clarity on customer preferences and needs, Keatext empowers businesses to cultivate meaningful relationships with their customers and respond effectively to their feedback.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

Uplift, Inc. is a fintech company specializing in digital lending specifically for travel and bookings. Founded in 2011 and based in Menlo Park, California, Uplift provides loans and credit facilities that allow individuals to pay for their travel expenses in monthly installments. The company operates a buy now, pay later solution, partnering with over 100 leading travel brands to offer personalized and flexible payment options. This approach not only helps consumers manage their budgets effectively but also enhances conversion rates and customer retention for its merchant partners. Uplift's innovative platform aims to make travel more accessible and affordable for a broader audience.

Persist AI specializes in enhancing the drug development process for pharmaceutical companies by utilizing artificial intelligence and automation technologies. By focusing on long-acting formulations, the company aims to significantly reduce the time required for pre-clinical formulation development from several years to just three months. This acceleration is achieved through methods such as automated drug release testing and high-throughput formulation screening. By streamlining these processes, Persist AI enables drug manufacturers to develop formulations 50% faster, ultimately contributing to improved patient outcomes and more efficient drug development.